Retatrutide Before and After: Trial Outcomes and Timelines

Weight-change timeline in trials

In Phase 2, average weight change separated from placebo during the early months and continued through the 48-week endpoint in higher-dose groups. Part of that period included dose escalation. The 12 mg group’s average curve had not reached a clear plateau at 48 weeks.

TRIUMPH-1 extended observation to 80 weeks. Lilly reported an average reduction of up to 28.3% in May 2026. That update is useful but remains a sponsor-reported Phase 3 result pending full publication and regulatory review.

What “before and after” means in research

A trial compares a defined baseline with scheduled measurements after randomization. Researchers report group averages, uncertainty intervals and thresholds reached by proportions of participants. This is more informative than selected photographs because it includes everyone assigned under the study’s statistical plan.

Factors that affect outcomes

• Randomized dose arm and ability to remain on the assigned protocol.
• Baseline weight, metabolic health and trial eligibility characteristics.
• Adherence to visits and standardized lifestyle guidance.
• Treatment discontinuation and the statistical estimand used.
• Normal variation in biological response and tolerability.

Why individual results vary

A mean is not a promise. Some participants lost more, some less and some discontinued treatment. Trial populations also exclude certain conditions and medication combinations, so the results cannot be generalized to every person. Long-term maintenance after stopping remains an important research question.